Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Sorbonne University, Hôpital Saint-Antoine, APHP, Paris, France

2 abstracts

Abstract
Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).
Org: Université de Poitiers et Centre Hospitalier Universitaire de Poitiers, INSERM U1313 and CIC 1082, Poitiers, France, Hôpital Haut Leveque, University Hospital, Pessac, France, ECSTRA, Centre de Recherche en Epidémiologie et Statistiques, INSERM UMR 1153, Paris, France, Lille University Hospital, Lille, France, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France,
Abstract
All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D.
Org: Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Poitiers, Vendée Departmental Hospital Centre, Hopital Cote de Nacre, Hematology Department, University Cancer Institute IUCT oncopôle, Toulouse, France,